Preliminary Program (August 8, 2022)

Integrated Continuous Biomanufacturing V

"Back to Barcelona: Progress & Potential of ICB"

October 9-13, 2022 **Dolce Sitges Barcelona Resort** Sitges, Spain

Conference Chairs

Ana Azevedo, Técnico Lisboa, Portugal Jason Walther, Sanofi, USA Rohini Deshpande, Amgen, USA





Engineering Conference International 32 Broadway, Suite 314 - New York, NY 10004, USA www.engconfintl.org - info@engconfintl.org

Sunday, October 9, 2022

14:00 – 16:30	Conference Check-in
16:30 – 16:45	Welcome
16:45 – 17:30	Keynote 1 TBD TBD
17:30 – 18:30	Panel Session on Digitalization Facilitated by Massimo Morbidelli, ETH Zurich, Switzerland
18:30 – 19:00	Free Time
19:00 – 20:00	Reception
20:00 – 21:30	Dinner
21:30 – 23:00	Social Hour

Monday, October 10, 2022

07:00 - 08:30	Breakfast
	Session 1: Breakthrough ICB technologies on the horizon Chairs: Astrid Dürauer, BOKU, Austria Michael Coolbaugh, Sanofi, USA
08:30 – 08:55	A truly continuous counter-current downstream Jon Coffman, AstraZeneca, USA
08:55 – 09:20	Democratizing global supply of recombinant proteins Kerry Love, Sunflower Therapeutics, USA
09:20 – 09:45	A fully continuous and modular monoclonal antibody purification process with capture via precipitation Todd Przybycien, Rensselaer Polytechnic Institute, USA
09:45 – 10:10	Exploring different medium exchange regimes in ultra scale-down models Marie Dorn, University College London, United Kingdom
10:10 – 10:35	2-stage continuous growth-decoupled biomolecules production using Escherichia coli – Towards microbial small-footprint manufacturing Juergen Mairhofer, enGenes Biotech GmbH, Austria
10:35 – 11:15	Coffee / Networking Break
	Poster Snapshot Session Chairs: Todd Przybycien, Rensselaer Polytechnic Institute, USA Mattia Sponchioni, Politecnico Di Milano, Italy Marcella Yu, Sutro Bio, USA
11:15 – 11:21	Overcoming key challenges during the upstream development of a continuus manufacturing process at 500L scale Leon Pybus, FUJIFILM Diosynth Biotechnologies, United Kingdom
11:21 – 11:27	Advanced control strategies for the continuous production of monoclonal antibodies Markus Kampmann, Sartorius, Corporate Research, Germany
11:27 – 11:33	Transcriptomics and modelling to understand the benefits of low perfusion rate Meeri Mäkinen, Cell Technology Group, Industrial Biotechnology KTH, Sweden
11:33 – 11:39	Understanding factors that cause product retention and fouling of hollow fiber filters in intensified perfusion processes Sri Madabhushi, Merck & Co., Inc., USA
11:39 – 11:45	Successful transition from fed-batch to continuous manufacturing within a mAb process development cycle Karthik P. Jayapal, Merck & Co., Inc., USA
11:45 – 11:51	Establishing a highly automated and digitalized end-to-end bioprocess Martin Purtscher, Baxalta Innovations GmbH, Austria

Monday, October 10, 2022 (continued)

11:51 – 11:57	Design & construction of a truly continuous and fully automated process skid for the production and purification of a monoclonal antibody Bernhard Sissolak, Bilfinger Life Science GmbH, Austria
11:57 – 12:03	Process Analytical Technology (PAT) for automated, real-time control of continuous manufacturing of mAbs Garima Thakur, Indian Institute of Technology, Delhi, India
12:03 – 12:09	Automated control of osmolality in a perfusion bioreactor system via in situ conductivity sensors Jeffrey Swana, Sanofi, USA
12:09 – 12:15	Enhanced process control of an integrated and scalable bioprocess for production and isolation of MSC-derived extracellular vesicles for cardiac repair Marta Costa, iBET, Portugal
12:15 – 12:21	Dynamic process control of continuous twin-column chromatography Thomas Müller-Späth, ChromaCon AG, Switzerland
12:21 – 12:27	Residence time distribution of continuous protein a chromatography Narges Lali, acib- Austrian Centre of Industrial Biotechnology, Austria
12:27 – 12:33	Plug-and-play software for mechanistic modelling of end-to-end continuous manufacturing of monoclonal antibodies Moo Sun Hong, Massachusetts Institute of Technology, USA
12:33 – 12:39	Process and cost modeling approaches for manufacturing operations utilizing multi-column chromatography applications James Angelo, Bristol Myers Squibb, USA
12:39 – 12:45	Pilot scale technical establishment and commercial scale business case on integrated continuous biomanufacturing Takuo Kawase, Chugai Pharmaceutical Co., Ltd., Japan
12:45 – 14:00	Lunch
	Session 2: Continuous manufacturing of emerging therapeutic modalities Chairs: Joseph Shultz, Evelo Biosciences, USA Cristina Peixoto, iBET, Portugal
14:00 – 14:25	The multidimensional evolution of ICB: New concepts, technology, and therapeutic modalities Konstantin Konstantinov, Codiak BioSciences, USA
14:25 – 14:50	Towards an integrated continuous manufacturing process of adeno- associated virus (AAVs) João Mendes, iBET, Portugal
14:50 – 15:15	Mechanistic modeling to predict titers and infected cells in the two-stage continuous production of a viral vaccine Krystian Ganko, Massachusetts Institute of Technology, USA

Monday, October 10, 2022 (continued)

15:15 – 15:40	Continuous manufacturing of lentiviral vectors Dale Stibbs, University College London, United Kingdom
15:40 – 16:05	Looking beyond the horizon: Exosomes at the vanguard of integrated continuous processing of bionanoparticles Aaron Noyes, Codiak BioSciences, USA
16:05 – 16:30	Progress towards making a global supply of microbial extracellular vesicles,100-times cheaper than a typical biologic Collin McKenna, Evelo Biosciences, Inc., USA
16:30 – 17:15	Coffee / Networking Break
17:15 – 18:00	Keynote 2 A race to contain a global pandemic: The development of the Pfizer/BioNTech mRNA vaccine Ranga Godavarti, Pfizer, USA
18:00 – 20:00	Poster Session 1 Chairs: Todd Przybycien, Rensselaer Polytechnic Institute, USA Mattia Sponchioni, Politecnico Di Milano, Italy Marcella Yu, Sutro Bio, USA
20:00 – 21:30	Dinner
21:30 – 23:00	Social Hour

Tuesday, October 11, 2022

07:00 - 08:30	Breakfast
	Session 3: The case for ICB industrialization Chairs: Jennifer Pollard, Merck & Co., USA Andrea Rayat, University College London, United Kingdom
08:30 – 08:55	From lab coats to hard hats: Implementation of GMP continuous manufacturing on the road to commercial readiness Mark Brower, MSD, USA
08:55 – 09:20	Business case for continuous mAb production with novel design strategies and enhanced control Catarina Neves, University College London, United Kingdom
09:20 – 09:45	Key enablers of continuous manufacturing success through a flexible J.POD® platform Eva Gefroh, Just Evotec Biologics, USA
09:45 – 10:10	GMP implementation of continuous manufacturing: A case study Neil Soice, Amgen, Inc., USA
10:10 – 10:35	Demonstration of a commercial scale end-to-end continuous purification process Chad Varner, Sanofi, USA
10:35 – 11:15	Coffee / Networking Break
11:15 – 12:45	Workshop 1: Standardization and modularization: A rising tide lifts all ICB processes Chairs: Chris Love, Massachusetts Institute of Technology, USA Paul Randolph, Janssen, USA
	Workshop 2: Promoting academic, industrial, government, and non-profit collaborations for next-generation biomanufacturing Chairs: John Erickson, NIIMBL, USA Kerry Love, Sunflower Therapeutics, USA Veronique Chotteau, KTH, Sweden
	Workshop 3: Continuous biomanufacturing: Opportunities and challenges for a sustainable future Chairs: Sara Badr, The University of Tokyo, Japan Priyanka Gupta, Sartorius Stedim, USA
12:45 – 14:45	Poster Session 2 and Lunch Chairs: Todd Przybycien, Rensselaer Polytechnic Institute, USA Mattia Sponchioni, Politecnico Di Milano, Italy Marcella Yu, Sutro Bio, USA
14:45 – 15:30	Keynote 3 FDA's progress in advanced manufacturing Larry Lee, FDA, USA
15:30 –	Outing followed by dinner on your own

Wednesday, October 12, 2022

07:00 – 08:30	Breakfast
	Session 4: ICB strategies to address industry challenges and opportunities
	Chairs: Lisa Connell-Crowley, Just-Evotec Biologics, USA Anurag S. Rathore, Indian Institute of Technology Delhi, India
08:30 – 08:55	Process intensification: Modeling the impact of technology and process scenario selection on cost, throughput, facility volume, footprint and sustainability
	Priyanka Gupta, Sartorius Stedim Biotech, USA
08:55 – 09:20	Development of a flexible and modular approach for integrated continuous biomanufacturing Michael Coolbaugh, Sanofi, USA
09:20 – 09:45	Highly automated bioburden-free continuous manufacturing biologics GMP operations: How to get there? Lara Fernandez Cerezo, Merck & Co., Inc., USA
09:45 – 10:10	Continuous downstream process of monoclonal antibody developed based on the process analysis/understanding and its validation Shuichi Yamamoto, Yamaguchi University, Japan
10:10 – 10:35	Intensified bioprocessing: Data, data, everywhere Marc Bisschops, Pall Biotech, Netherlands
10:35 – 11:15	Coffee / Networking Break
11:15 – 12:45	Workshop 4: GMP implications for fully E2E processes: Are we fulfilling our expectations? Chairs: Mark Brower, MSD, USA Neil Soice, Amgen, Inc., USA
	Workshop 5: Solving the problems of ICB process development to unlock the full potential of continuous manufacturing Chairs: David Garcia, Novartis Pharma, Switzerland Steven Cramer, Rensselaer Polytechnic Institute, USA
	Workshop 6: Risk assessment for the adoption of ICB: What factors still stand in our way? Chairs: Julie Kozaili, Asahi Kasei Bioprocess, USA Chris Hwang, Transcenta Therapeutics, USA
12:45 – 14:00	Lunch
	Session 5: Integrated control strategies to advance ICB Chairs: Bernt Nilsson, Lund University, Sweden Irina Ramos, AstraZeneca, USA
14:00 – 14:25	Pilot-scale integrated continuous biomanufacturing for monoclonal antibodies including mild pH Veronique Chotteau, KTH, Sweden

Wednesday, October 12, 2022 (continued)

14:25 – 14:50	Design considerations when scaling from 3-L to 3000-L or larger Kenneth Lee, AstraZeneca, USA
14:50 – 15:15	Real-time process analytical technology: Fluorescent dye-based miniaturized sensor for aggregate detection Mariana Neves Sao Pedro, Delft University of Technology, Netherlands
15:15 – 15:40	Enabling PAT in insect cell bioprocesses: A monitoring toolbox for rAAV production Inês A. Isidro, iBET, Portugal
15:40 – 16:20	Coffee / Networking Break
	Session 6: Application of smart manufacturing tools to ICB Chairs: Cenk Ündey, Amgen, USA Christoph Herwig, TU Wien, Austria
16:20 – 16:45	Mass spectrometry as a part of the PAT toolkit in bioprocess Tiziano Brogna, Merck, Switzerland
16:45 – 17:10	Advanced process control and process analytical technology for continuous bioprocessing Lukas Kuerten, Centre for Process Innovation Ltd., United Kingdom
17:10 – 17:35	Model based control of continuous bioprocesse Anurag Rathore, Indian Institute of Technology, Delhi, India
17:35 – 18:00	Advanced process control strategies for continuous influenza viral particle production Pavan Inguva, Massachusetts Institute of Technology, USA
18:00 – 18:45	Award Keynote TBD Veena Warikoo, AstraZeneca, USA
18:45 – 19:30	Free Time
19:30 – 20:30	Reception
20:30 – 22:30	Banquet and Awards Ceremony
22:30 – 23:30	Social Hour

Thursday, October 13, 2022

07:00 – 09:00 Breakfast and Departure